Fig. 5.

Composite efficacy and safety profile of different rivaroxaban doses compared with enoxaparin/VKA for the treatment of deep vein thrombosis in two phase II dose-finding studies. a 21-day thrombus regression and major bleeding; b 3-month thrombus burden and clinically relevant bleeding [52, 53]. Rivaroxaban bars that remained below the line performed better overall than enoxaparin/VKA. Clinically relevant bleeding was the composite of major and non-major clinically relevant bleeding. The composite outcome depicted here was not a pre-defined endpoint of these trials. bid twice daily, od once daily, VKA vitamin K antagonist